Tell me again why we canāt use renal SBRT in the UK?!? 100% local control is hard to beat. Masterclass by @_ShankarSiva #ASTRO24
@alison_tree @_ShankarSiva @HarshaniGreen @fizzy_cyst @PattyDiezH We can use it. It is a local and network based decision. We just wonāt get paid for it until it is fully commissioned by NHS England. That puts centres off. A decision from NHS England is coming soonā¦.
@alison_tree @_ShankarSiva @cpeedell @HarshaniGreen @fizzy_cyst @PattyDiezH Thanks to @_ShankarSiva efforts and our urology team lead by @declangmurphy , we are seeing quite significant increase in numbers over last few years.
@alison_tree @_ShankarSiva @cpeedell @HarshaniGreen @fizzy_cyst You should tag NHSEā¦ Also, in England only. You can get treated in all other regions of the UKā¦
@alison_tree @_ShankarSiva @cpeedell @HarshaniGreen @fizzy_cyst @PattyDiezH At our centre, urologists, medical oncologists, and radiation oncologists work collaboratively together in a multidisciplinary team to ensure that all renal cell carcinoma patients are seen by the appropriate specialists. @fredhutch
@alison_tree @_ShankarSiva @cpeedell @fizzy_cyst @PattyDiezH Staying hopeful & trusting in the process šš½
@alison_tree @_ShankarSiva @cpeedell @HarshaniGreen @fizzy_cyst @PattyDiezH Renal SBAR is a perfectly valid option and I have always reminded MDT of this option whether its London or Portsmouth or India
@alison_tree @_ShankarSiva @cpeedell @HarshaniGreen @fizzy_cyst @PattyDiezH All I know is that if a certain surgical intervention's LC approached anything like this it would become immediate SOC...
Too much enthusiasm. Hardly listen to/read about cons. 1. Similar to other cancers, for RCC trials as well, definition of patient complexity and medical inoperability must be delineated. Essential to limit investigator bias. 2. Functional outcomes are an issue. 15 ml/min average loss & 4% dialysis rate is something compared to PN. 3. Many patients would have been perfect candidates to AS (age, comorbidities, renal mass characteristicsā¦). However, advantages of AS are not mentioned. pubmed.ncbi.nlm.nih.gov/39084966/
@alison_tree @_ShankarSiva @cpeedell @HarshaniGreen @fizzy_cyst @PattyDiezH Happy to send a delegation of very happy customers to advocate š. FANTASTIC option in the appropriate clinical scenario šŖšŖ. Thanks Shankar for the tireless work!
